Research & Development: Page 72


  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Safety First Era

    The classwide requirement for Risk Evaluation and Mitigation Strategies (REMS) for opioid products is likely to have a profound impact on the pharmaceutical industry and healthcare. While most REMS involve only a medication guide — which is likely to have little impact on the prescribing process ...

    By PharmaVoice Team • Nov. 10, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    RNAI Technology

    Coming of Age: RNAi Technology As advances in genetics ­continue to improve our understanding of ­disease, RNAi will have the opportunity to create entirely new classes of medicines. Researchers say RNA-based therapeutic technology will have a tremendous impact on pharmaceutical research in the n...

    By Denise Myshko • Nov. 10, 2009
  • cancer R&D Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Oncology R&D

    Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

    By PharmaVoice staff
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Supply Chain Strategies

    Companies need to evaluate their business through their value streams rather than by individual processes or components. ccording to Bob Silvers, managing director, at SSA & Co., by applying the rigors of Lean Six Sigma to underperforming areas, pharmaceutical companies can completely transfo...

    By Denise Myshko • Nov. 10, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Executive Suite

    Meeting challenges head-on David E. I. Pyott, CBE Chairman of the Board and CEO Allergan Inc. Allergan draws stability, strength, and value from its growth equation — a business model that balances diverse specialties with a focused approach and a leadership presence in markets around the globe. ...

    By PharmaVoice Team • Nov. 10, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    On the Calendar

    November 16-17 Pharmaceutical Coverage & Reimbursement Conference Washington, D.C. Q1 Productions, q1productions.com November 16-17 The 3rd Pediatric Clinical Trials Grand Hyatt Washington, Washington, D.C. ExL Pharma, exlpharma.com November 17-18, 2009 13th Advanced Forum on Structuring, Neg...

    By PharmaVoice Team • Nov. 9, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Index

    Julian Adams, Ph.D. President, Research and ­Development and Chief Scientific Officer, Infinity ­Pharmaceuticals Inc. Brent Ahrens. General Partner, Canaan Partners Kenneth C. Aldrich. CEO, Chairman, and Co-Founder, ­International Stem Cell Corp. Meryl Allison. Principal, Deloitte Consulting Karl...

    By PharmaVoice Team • Nov. 9, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    PharmaTrax

    Service Consolidation Recommended for Clinical trial Offices Emerging centralized clinical trial offices (CTOs) are among the newest developments within the research administration infrastructure of academic health centers. Little uniformity exists in the structure or functions of existing CTOs, ...

    By PharmaVoice Team • Nov. 9, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    What's New

    inVentiv Health’s recently launched risk evaluation and mitigation strategy (REMS) offering provides pharmaceutical and biotechnology clients with a customizable suite of REMS-related services that can be delivered through a single, integrated program. In an effort to assure safe use of prescript...

    By PharmaVoice Team • Nov. 9, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    PharmaTrax

    buster brands,”says David Lipson,forecasting practice leader at IMS Global Consulting.“But we are not see ing the avalanche that some feared. Although the number of major new product launches was smaller than usual last year, the genuine value provided by medicines introduced over the past dozen ...

    By PharmaVoice Team • Nov. 3, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The End of the Paper Chase

    Responses to an ongoing survey and face to face discussions with executives from pharmaceutical and biotech companies reveal their greatest concerns and hopes as they begin to streamline the clinicaltrials process. IN AN EXCLUSIVE WITH PHARMAVOICE, ELLEN SEMPLE,VP, MARKETING, CB TECHNOLOGIES INC....

    By PharmaVoice Team • Nov. 2, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Talent Pool

    Pharma POOL Robert GELBARD ICN Pharmaceuticals Appoints Former Ambassador to Head International Efforts Former Ambassador Robert Gelbard joins ICN Pharmaceuticals Inc. as senior VP for international affairs and government relations. Mr. Gelbard is the com pany representative with foreign governme...

    By PharmaVoice Team • Nov. 2, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    E-Media

    NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES BioSpace Inc., a provider of Webbased products and information services to the life sciences industry, has formed a collaboration with MediBic, a Japanese bioventure company, to exchange information in an effort to support new biot...

    By PharmaVoice Team • Nov. 2, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    What's New

    WHAT’S NEW NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES Noonan Russo Communications has agreed to merge its operations with the public relations division of Euro RSCG Healthview, establishing a new company — Noonan Russo Presence Euro RSCG. The new entity, a differentiated communicatio...

    By PharmaVoice Team • Oct. 30, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    PharmaTrax

    Extending its line of therapeutic class research, NOP World Health has added Diabetes Patient Market Study to its portfolio of disease state research. The staff of diabetes experts who support the study, which has been produced by NOP World Health’s sister com pany, RoperASW since 1989, will be i...

    By PharmaVoice Team • Oct. 30, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Pharma Outlet

    The pharmaceutical industry is facing a crucial short age in the area of clinical trials. With an estimated 4,360 new drugs in the pipeline, it has become an increasing challenge for the industry to recruit both qualified patient volunteers and experienced researchers. Only an estimated 5 million...

    By Kathleen H. Drennan • Oct. 29, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Brave New Digital World

    Pharma companies must be bold and confident in their deployment of electronic solutions or risk being left behind on the technological superhighway. Patients and physicians are migrating in droves toward Web- and mobile-based healthcare solutions. The overall number of e-health consumers who go o...

    By PharmaVoice Team • Oct. 27, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    What's Missing in eSolutions: Enabling the Redefinition of Clinical Development

    There’s something missing from the eSolutions discussion. In fact, there are two key missing links: n eSolutions that are no more than bridges between silos will not meet the needs of a rapidly changing clinical development environment; and n Strategies, pilots, and initial use of eSolutions are ...

    By PharmaVoice Team • Oct. 27, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    eClinical Feedback: Why Sponsors Need an Integrated, Closed-Loop Clinical Process

    David Gemzik, Vice President, Implementation Services Sean Cheng, Senior Product Marketing Manager Faced with slowing pipe lines and spiraling costs in new drug development, sponsors in recent years have been trying to conquer the last frontier in process improvement: R&D. However, increasing...

    By PharmaVoice Team • Oct. 27, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    3 PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh DIRECTOR OF SALES Darlene Kwiatkowski CONTRIBUTING EDITORS Virginia Kirk Denise Myshko Elisabeth Pena Kim Ribbink Deborah Ruriani Lynda Sears Copyright 2002 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume Two, ...

    By Taren Grom • Oct. 23, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    The Nose Knows

    Many of the properties that make the nose an effective way for an illicit drug user to get a “fix” are actually qualities that doctors and patients are seeking for legitimate treatments — a noninjection form that delivers medication in highly targeted, quickly absorbed doses. Britannia Pharmaceut...

    By Taren Grom • Oct. 23, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    PharmaTrax

    $7 Billion in revenue predicted for ADVANCED DRUG DELIVERY SYSTEMS by 2005 The market for drugs employing advanced drug delivery technologies will surpass $7 billion by 2005,according to a study from Kalorama Information.The market segment has seen doubledigit growth over the past few years, and ...

    By PharmaVoice Team • Oct. 23, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Pharma Outlet

    Despite a history of new product launches, strong growth, and increased research spending, it is clear that the pharmaceutical industry is in a period of major transition. The challenge facing the industry is one of creating a sustainable pipeline that can generate the longterm growth needed to f...

    By Kevin Starr • Oct. 23, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Table of Contents

    on the cover High Stakes: HITECH The pharma industry could come out a winner in the new game of HITECH (Health Information Technology for Economic and Clinical Health Act), if companies can come up with the right ante. FEATURES Publication Planning Update Title VIII of FDAAA, which requires the p...

    By PharmaVoice Team • Sept. 30, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Christine Bunt: Converging on a Solution

    Converging on a Solution Moving from diagnostics to pharmaceuticals, from Europe to the United States, and ultimately from big pharma to a small startup company is not for everybody. But Christine Bunt has the confidence, knowledge, and business acumen to take on any challenge, and she revels in ...

    By Kim Ribbink • Sept. 28, 2009
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Last Word

    AstraZeneca’s Dr. Larry Furlong Outlines the Company’s Lean Sigma ­Program for Process Improvement AstraZeneca is applying the business improvement methodology Lean Sigma to discovery in an attempt to shorten project lead times and increase candidate quality. AstraZeneca’s Larry Furlong, Ph.D., i...

    By PharmaVoice Team • Sept. 28, 2009